A planned hepatitis B vaccine trial in Guinea-Bissau will not proceed, the study’s principal investigator told The BMJ. Frederik Schaltz-Buchholzer reported that the country’s military government “has announced that they do not authorize the trial,” and that, as a result, the study “will therefore not happen.” The BMJ article carries this direct confirmation and treats the government refusal as the proximate cause of the cancellation.
The wording used by the investigator, as presented in the BMJ account, is unequivocal. Officials in Bissau communicated a decision to decline authorisation. The source did not provide the government’s formal statement text beyond the quoted paraphrase from the investigator, and it did not publish any regulatory correspondence or the legal instrument cited by national authorities.
Two days before the investigators’ confirmation, Guinea-Bissau’s judicial police searched the facilities of the Bandim Health Project in the country’s capital, Bissau. The BMJ reports that the police seized a batch of hepatitis B vaccines during that search. In a statement, the judicial police characterised the raid as part of an “investigative procedure” intended to clarify the circumstances related to the vaccines.
The BMJ article does not include further operational details from the police release—there is no description in the source of the legal grounds invoked for the search, the size or lot numbers of the vaccines taken, the immediate custodial arrangements, or whether charges were filed. The single public account of the raid recorded in the BMJ is the police description of the action as investigative; no court documents or affidavits are appended to that account in the source text.
The trial team named in the BMJ report includes principal investigator Frederik Schaltz-Buchholzer and co-principal investigator Christine Stabell Benn. Both are affiliated with the Bandim Health Project, which the BMJ describes as a Danish-run research organisation operating in Guinea-Bissau. The article identifies the Bandim Health Project as the local research presence where the raid occurred and where the investigators are based.
Beyond naming the investigators and the institutional affiliation, the BMJ story does not provide biographical or role-specific details for the individuals, and it does not publish institutional responses from the Bandim Health Project beyond the quoted investigator statement. The source limits the public record to the investigators’ confirmation that the trial will not proceed and to the police account of the search.
The BMJ report is focused on the cancellation and the police action; it does not supply core trial documentation. The source did not report the trial protocol, the study design, primary or secondary endpoints, target enrolment, inclusion or exclusion criteria, methods for informed consent, vaccine dosing schedules, manufacturing or lot details, or the sponsor’s regulatory submissions. The article likewise does not indicate whether the investigators had obtained any prior ethical approvals from national or international review boards.
The absence of those operational and regulatory details is explicit in the BMJ account. Readers seeking precise methodological or ethical documentation will need to consult primary study documents or statements from the investigators or the Bandim Health Project; those materials are not included in the source article.
The BMJ article leaves several concrete questions unanswered. The source does not report the legal basis for the police action, whether the seizure followed an official administrative or judicial order, or if the seized vaccine batch has been made available for independent inspection. The story does not say whether Guinea-Bissau health authorities or the Bandim Health Project intend to challenge the refusal of authorisation or to seek alternative approvals.
Other practical matters are likewise unreported: the BMJ does not document community engagement efforts for the planned trial, the intended participant population, or any risk–benefit assessments made available to local stakeholders. The investigators’ quoted statement confirms the cancellation but the article does not include further commentary from government health officials, independent regulators, or legal representatives.
Limitations and next steps that remain open within the source record include whether the judicial investigation will proceed to formal charges, whether the Bandim Health Project will release internal documentation about the planned study, and whether external funders or partner institutions have reacted. The BMJ report sets out the sequence—police search, vaccine seizure, government refusal, investigator confirmation—but it does not provide the documentary trail that would answer these operational and legal questions.
This account is based solely on the BMJ report cited. Where the source did not report specific trial operational, regulatory, or investigative details, this article explicitly notes that absence rather than infer facts beyond the BMJ text.